Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pom-dex versus Pom-cyclo-dex for relapsed multiple myeloma during lenalidomide maintenance
2015-001142-28Phase 3Terminated
- Sponsor
- Fondazione EMN Italy
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pomalidomide, cyclophosphamide, dexamethasone and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Fondazione EMN Italy. Primary endpoint: Overall survival. Started Nov 2020; status: terminated.
02
Drugs
pomalidomidecyclophosphamidedexamethasonelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-001142-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001142-28.